China Pharma Holdings (CPHI) Liabilities and Shareholders Equity (2010 - 2026)

China Pharma Holdings has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $45.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 217.53% year-over-year to $45.1 million; the trailing twelve-month figure through Mar 2026 stood at $105.7 million (up 86.01% YoY), and the FY2025 full-year result was $31.0 million, up 108.22% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $45.1 million, up from $31.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $45.1 million in Q1 2026, with the low at $13.5 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $18.6 million across 5 years, with a median of $16.2 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 21.48% — and 2026, when it soared 217.53%.
• China Pharma Holdings' Liabilities and Shareholders Equity stood at $17.8 million in 2022, then declined by 7.39% to $16.5 million in 2023, then decreased by 9.6% to $14.9 million in 2024, then soared by 108.22% to $31.0 million in 2025, then soared by 45.63% to $45.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $45.1 million (Q1 2026), $31.0 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.